vs
Side-by-side financial comparison of Tecnoglass Inc. (TGLS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $129.7M, roughly 1.9× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 2.4%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 12.8%).
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
TGLS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $245.3M | $129.7M |
| Net Profit | $26.1M | — |
| Gross Margin | 40.0% | 98.0% |
| Operating Margin | 18.3% | -25.0% |
| Net Margin | 10.6% | — |
| Revenue YoY | 2.4% | 73.4% |
| Net Profit YoY | -44.5% | — |
| EPS (diluted) | $0.57 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $245.3M | $129.7M | ||
| Q3 25 | $260.5M | $164.9M | ||
| Q2 25 | $255.5M | $114.4M | ||
| Q1 25 | $222.3M | $81.7M | ||
| Q4 24 | $239.6M | $74.8M | ||
| Q3 24 | $238.3M | $62.9M | ||
| Q2 24 | $219.7M | $54.1M | ||
| Q1 24 | $192.6M | $41.4M |
| Q4 25 | $26.1M | — | ||
| Q3 25 | $47.2M | $25.7M | ||
| Q2 25 | $44.1M | $-12.8M | ||
| Q1 25 | $42.2M | $-41.2M | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $49.5M | $-54.8M | ||
| Q2 24 | $35.0M | $-70.4M | ||
| Q1 24 | $29.7M | $-136.1M |
| Q4 25 | 40.0% | 98.0% | ||
| Q3 25 | 42.7% | 99.0% | ||
| Q2 25 | 44.7% | 98.7% | ||
| Q1 25 | 43.9% | 94.3% | ||
| Q4 24 | 44.5% | 96.6% | ||
| Q3 24 | 45.8% | 97.4% | ||
| Q2 24 | 40.8% | 96.2% | ||
| Q1 24 | 38.8% | 96.4% |
| Q4 25 | 18.3% | -25.0% | ||
| Q3 25 | 25.1% | 15.1% | ||
| Q2 25 | 24.0% | -11.1% | ||
| Q1 25 | 26.7% | -52.2% | ||
| Q4 24 | 28.0% | -81.2% | ||
| Q3 24 | 28.4% | -89.3% | ||
| Q2 24 | 23.3% | -125.1% | ||
| Q1 24 | 21.3% | -336.5% |
| Q4 25 | 10.6% | — | ||
| Q3 25 | 18.1% | 15.6% | ||
| Q2 25 | 17.3% | -11.1% | ||
| Q1 25 | 19.0% | -50.4% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.8% | -87.1% | ||
| Q2 24 | 15.9% | -130.1% | ||
| Q1 24 | 15.4% | -328.9% |
| Q4 25 | $0.57 | $0.04 | ||
| Q3 25 | $1.01 | $0.28 | ||
| Q2 25 | $0.94 | $-0.14 | ||
| Q1 25 | $0.90 | $-0.47 | ||
| Q4 24 | $1.00 | $-0.71 | ||
| Q3 24 | $1.05 | $-0.70 | ||
| Q2 24 | $0.75 | $-0.91 | ||
| Q1 24 | $0.63 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.1M | $93.0M |
| Total DebtLower is stronger | $174.4M | — |
| Stockholders' EquityBook value | $713.1M | $114.8M |
| Total Assets | $1.3B | $605.2M |
| Debt / EquityLower = less leverage | 0.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.1M | $93.0M | ||
| Q3 25 | $127.1M | $110.9M | ||
| Q2 25 | $140.9M | $75.2M | ||
| Q1 25 | $160.2M | $61.9M | ||
| Q4 24 | $137.5M | $58.5M | ||
| Q3 24 | $124.8M | $36.4M | ||
| Q2 24 | $129.5M | $32.3M | ||
| Q1 24 | $138.8M | $43.3M |
| Q4 25 | $174.4M | — | ||
| Q3 25 | $114.7M | — | ||
| Q2 25 | $110.6M | — | ||
| Q1 25 | $110.6M | — | ||
| Q4 24 | $111.1M | — | ||
| Q3 24 | $126.8M | — | ||
| Q2 24 | $144.7M | — | ||
| Q1 24 | $160.9M | — |
| Q4 25 | $713.1M | $114.8M | ||
| Q3 25 | $764.0M | $73.6M | ||
| Q2 25 | $736.0M | $32.7M | ||
| Q1 25 | $685.1M | $32.8M | ||
| Q4 24 | $631.2M | $59.1M | ||
| Q3 24 | $613.3M | $-30.5M | ||
| Q2 24 | $574.8M | $15.1M | ||
| Q1 24 | $573.6M | $74.1M |
| Q4 25 | $1.3B | $605.2M | ||
| Q3 25 | $1.2B | $538.6M | ||
| Q2 25 | $1.2B | $555.3M | ||
| Q1 25 | $1.1B | $548.8M | ||
| Q4 24 | $1.0B | $594.1M | ||
| Q3 24 | $996.3M | $504.4M | ||
| Q2 24 | $942.5M | $551.1M | ||
| Q1 24 | $981.6M | $663.5M |
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.25× | — | ||
| Q1 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.0M | $60.7M |
| Free Cash FlowOCF − Capex | $11.4M | — |
| FCF MarginFCF / Revenue | 4.7% | — |
| Capex IntensityCapex / Revenue | 8.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.0M | $60.7M | ||
| Q3 25 | $40.0M | $14.3M | ||
| Q2 25 | $17.9M | $5.0M | ||
| Q1 25 | $46.9M | $-42.2M | ||
| Q4 24 | $61.1M | $-35.7M | ||
| Q3 24 | $41.5M | $-42.5M | ||
| Q2 24 | $34.5M | $-40.2M | ||
| Q1 24 | $33.4M | $-119.0M |
| Q4 25 | $11.4M | — | ||
| Q3 25 | $21.2M | $14.2M | ||
| Q2 25 | $-14.7M | — | ||
| Q1 25 | $16.5M | — | ||
| Q4 24 | $35.4M | — | ||
| Q3 24 | $17.8M | — | ||
| Q2 24 | $14.2M | $-40.3M | ||
| Q1 24 | $23.6M | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 8.2% | 8.6% | ||
| Q2 25 | -5.7% | — | ||
| Q1 25 | 7.4% | — | ||
| Q4 24 | 14.8% | — | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | 6.5% | -74.5% | ||
| Q1 24 | 12.2% | — |
| Q4 25 | 8.0% | — | ||
| Q3 25 | 7.2% | 0.1% | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 13.7% | — | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 9.9% | 0.0% | ||
| Q2 24 | 9.2% | 0.2% | ||
| Q1 24 | 5.1% | 0.0% |
| Q4 25 | 1.19× | — | ||
| Q3 25 | 0.85× | 0.56× | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 1.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
